Nektar Therapeutics (FRA:ITH) Other Operating Expense : €-0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics Other Operating Expense?

Nektar Therapeutics's Other Operating Expense for the three months ended in Mar. 2024 was €0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.00 Mil.

Nektar Therapeutics's quarterly Other Operating Expense increased from Sep. 2023 (€-0.00 Mil) to Dec. 2023 (€-0.00 Mil) and increased from Dec. 2023 (€-0.00 Mil) to Mar. 2024 (€0.00 Mil).

Nektar Therapeutics's annual Other Operating Expense increased from Dec. 2021 (€-0.00 Mil) to Dec. 2022 (€0.00 Mil) but then stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Nektar Therapeutics Other Operating Expense Historical Data

The historical data trend for Nektar Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Other Operating Expense Chart

Nektar Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

Nektar Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Operating Expense	Get a 7-Day Free Trial															-	-	-	-	-

Nektar Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

Nektar Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics (FRA:ITH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (FRA:ITH) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

NKTR:USA

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Nektar Therapeutics (FRA:ITH) Headlines

No Headlines